The Fluoroless-CSP Trial Using Electroanatomic Mapping

NCT ID: NCT03903107

Last Updated: 2025-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-26

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to assess the feasibility, accuracy and safety of performing fluoroless (or low fluoro) conduction system pacing utilizing electro-anatomic mapping (EAM) with the CARTO 3 mapping system (Biosense Webster Inc, Irvine, CA) in comparison to a group of patients undergoing conventional conduction system pacing (CSP) Implants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this study is to assess the feasibility, accuracy and safety of performing fluoroless (or low fluoro) conduction system pacing utilizing electro-anatomic mapping (EAM) with the CARTO 3 mapping system (Biosense Webster Inc, Irvine, CA) in comparison to a group of patients undergoing conventional conduction system pacing (CSP) Implants.

In this study, we plan to randomize patients to fluoroscopy guided CSP vs 3D mapping guided CSP implants with low/zero fluoroscopy. The study with assess if 3D EAM guided implants can be performed successfully and without any significant increase in device implant related complications.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sinus Node Dysfunction Heart Block AV LBBB Heart Failure, Systolic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

CSP can be achieved successfully and safely utilizing electro-anatomic mapping (EAM) with the CARTO 3mapping system
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Conventional Conduction System Pacing(CSP) using fluoroscopy

Subjects in this arm will receive Conduction System Pacing(CSP) using conventional fluoroscopy technique.

Group Type PLACEBO_COMPARATOR

Conventional fluoroscopy guided Conduction System Pacing(CSP)

Intervention Type PROCEDURE

conventional standard approach Conduction System Pacing(CSP) using fluoroscopy

Fluoroless Conduction System Pacing(CSP) utilizing EAM with the CARTO 3 mapping system

Subjects in this arm will receive Conduction System Pacing(CSP) utilizing electroanatomic mapping system to eliminate or minimize fluoroscopic exposure.

Group Type EXPERIMENTAL

Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)

Intervention Type PROCEDURE

Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Conventional fluoroscopy guided Conduction System Pacing(CSP)

conventional standard approach Conduction System Pacing(CSP) using fluoroscopy

Intervention Type PROCEDURE

Electroanatomic Mapping (Fluoroless) guided Conduction System Pacing(CSP)

Conduction System Pacing(CSP) using electroanatomic mapping system with no or minimal fluoroscopy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years
* Indication for Permanent Pacemaker implantation or implantation of Cardiac Resynchronization Therapy Device

Exclusion Criteria

* Existing cardiac device including Pacemaker or Cardiac Resynchronization Therapy device
* Inability of patient capacity to provide consent for themselves either due to medical or psychiatric comorbidity
* Pregnancy
* Difficulty with follow-up
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rush University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rush University Medical Center

Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Sharma PS, Huang HD, Trohman RG, Naperkowski A, Ellenbogen KA, Vijayaraman P. Low Fluoroscopy Permanent His Bundle Pacing Using Electroanatomic Mapping: A Feasibility Study. Circ Arrhythm Electrophysiol. 2019 Feb;12(2):e006967. doi: 10.1161/CIRCEP.118.006967.

Reference Type RESULT
PMID: 30704289 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18090701

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BIO|CONCEPT.BIOMONITOR III
NCT03850327 COMPLETED NA
Fluoroless Conduction System Implant
NCT07094217 NOT_YET_RECRUITING